| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $383.0M | +10.1% |
| SG&A Expense | $142.2M | +8.5% |
| Operating Income | -$525.2M | -9.6% |
| Income Tax | $0 | — |
| Net Income | -$477.9M | -7.3% |
| EPS (Basic) | -$0.94 | +2.1% |
| EPS (Diluted) | -$0.94 | +2.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $140.9M | -1.2% |
| Short-term Investments | $769.9M | -17.1% |
| Current Assets | $922.3M | -14.9% |
| Total Assets | $1.32B | -12.0% |
| Current Liabilities | $64.9M | +13.6% |
| Total Liabilities | $164.5M | +1.7% |
| Stockholders' Equity | $1.16B | -13.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$274.6M | -14.4% |
| Capital Expenditures | $62.1M | -26.5% |
| Investing Cash Flow | $128.9M | +184.5% |
| Financing Cash Flow | $144.0M | -52.0% |
| Free Cash Flow | -$336.7M | -3.7% |